logo-loader

Archer Exploration progressing towards quantum computing chip development

Last updated: 21:45 25 Apr 2019 EDT, First published: 21:42 25 Apr 2019 EDT

Nano Science Hub cleanroom
Nano Science Hub cleanroom

Archer Exploration Ltd’s (ASX:AXE) vision is to build a long term and viable minerals and materials development business focusing on the key areas related to quantum technology, human health and reliable energy.

These three themes were targeted during the three-month period ending March 31, 2019, as they have associated industries with exponential growth opportunities.

Archer executive chairman Greg English said on the company’s third quarter activities: “We successfully launched the 12CQ Project, with the aim of building a carbon-based quantum computing chip that integrates critical materials from our inventory that would form the future basis of room-temperature quantum technology in modern consumer electronic devices.

 

“During the quarter we appointed Dr Martin Fuechsle as Archer’s Quantum Technology Manager and began building chip prototypes at the Research & Prototype Foundry Core Research Facility at the University of Sydney Nanoscience Hub.

“The production of spherical graphite from Campoona graphite using small scale mechanical processes was a great achievement for Archer.

READ: Archer Exploration produces spherical graphite suitable for lithium battery from Campoona deposit

“We were able to convert a 95% graphite concentrate into a high-quality spherical graphite which may allow us to more efficiently purify the graphite after, rather than before, the production of the spherical graphite.

“The drilling program at Blue Hills were positive, showing that the rocks have undergone alteration and the drilling results support the concept that the exposed mineralisation is proximal in nature to an inferred intrusion or intrusions located at depth immediately east of Hood, Hawkeye and Katniss”.

READ: Archer Exploration review suggests potential for copper-gold system at Blue Hills

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 28 minutes ago